1 mL BAC
2.5 units
resulting U-100 draw
- Concentration
- 10 mg/mL
- BAC added
- 1 mL
SinglePreclinicalPreclinicalVery Low confidenceSourced
5-Amino-1MQ
A small-molecule NNMT inhibitor with cell and animal metabolic research. It is not a peptide and no validated human protocol has been established.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
A community-provenance subcutaneous titration from an authenticated research forum, from about 250 mcg up to roughly 1 mg daily. Injectable reports only, not a validated schedule; oral capsule use is a separate route.
Reported maximum quantity
Titration to about 1 mg (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.Reported quantities by phase
Select a point for its calculation examples- Start low250 mcgInjectable reports begin near 250 mcg; a minority run far higher (10-50 mg) and a supplier suggested 12.5-25 mg every other day.
- Titrate500 mcg+250 mcgSubcutaneous reports titrate upward over several weeks toward the common ~1 mg landing point.
- Maintenance (6 days/week)1 mg+500 mcgQuantities cluster around 0.5-2 mg daily, most settling near 1 mg, in 6-8 week cycles.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 250 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw7.5 U
20-30 U reference band
2 mL BAC
5 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 2 mL
3 mL BAC
7.5 units
resulting U-100 draw
- Concentration
- 3.333 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 10 mg research vial
2.5 mg once daily on days 1-2, then 5 mg once daily; the guide also discusses twice-daily use at the same per-administration quantities
This is a community-derived schedule, not a human clinical regimen. No controlled human administration study validates the route, escalation or duration.
View sourceCommunity GuideOral in community reportsDaily during reported cycles
online research community discussion
Oral use clustered around 50-150 mg daily for about 21-30 days, often followed by an equal or otherwise unspecified washout
The archive explicitly says there is no human protocol and no defensible injectable schedule. It also records chloride-versus-iodide uncertainty and much higher outliers; raw/peptide-education/pe-5amino1mq.md:19-22 and raw/expert-posts/ep-5amino1mq-thyroid.md:64-147.
View sourceCommunity GuideSubcutaneous or oral in reportsDaily to 6 days per week, cycled
authenticated research-forum (Peppys) reports and expert commentary
Subcutaneous reports begin around 250 mcg and titrate to roughly 0.5-2 mg daily (most land near 1 mg), run about 6 days a week in 6-8 week cycles; a separate oral capsule route is reported around 30-50 mg daily with some citing 100-200 mg, and a supplier-suggested injectable schedule of 12.5 mg every other day rising to 25 mg conflicts sharply with the community sub-milligram injections
Forum provenance from an authenticated archive with usernames omitted. The archive states human dosing is unsettled, quantities range from 250 mcg to 25-50 mg, and the subcutaneous and oral routes are kept separate rather than interconverted.
View sourceEvidence summary
A small-molecule NNMT inhibitor with cell and animal metabolic research. It is not a peptide and no validated human protocol has been established.
Protocol basis
The page is based on preclinical NNMT-inhibition studies and therefore reports no human administration protocol.
Community provenance (Peppys)
An authenticated research-forum archive records a low subcutaneous titration that begins near 250 mcg and works up to roughly 1 mg daily, run about six days a week in six-to-eight-week cycles. The same archive keeps an oral capsule route separate at around 30-50 mg daily, with a few reports of 100-200 mg, and it notes a supplier-suggested injectable schedule of 12.5-25 mg every other day that conflicts sharply with the community sub-milligram injections. The archive states that human dosing is unsettled and logs quantities anywhere from 250 mcg to 25-50 mg. Usernames are omitted and figures are recorded as community provenance without endorsement; the planner above reproduces the arithmetic of the reported subcutaneous quantities rather than validating them.
What remains uncertain
Human safety, pharmacokinetics, target engagement and clinical outcomes are unknown.
Warnings and contraindications
No controlled human administration evidence was identified.
Rodent metabolic study quantities cannot be converted into a human schedule.
Identity, oral bioavailability and long-term NNMT inhibition risks remain uncertain.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.